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Abstract
The new percutaneous mitral valve repair techniques are at an early stage. Preliminary series show
that they are feasible; however, they need to be further evaluated in comparison with contemporary
treatment to accurately assess their efficiency. Potential applications may benefit high-risk patients
after thorough evaluation.
Introduction and context
Mitral regurgitation (MR) represents more than 30% of
native valve disease [1-3]. The good results of surgery,
particularly valve repair, set a high standard for future
percutaneousvalveintervention[4-6].However,incurrent
practice worldwide, surgery is denied in many patients
with severe valvular heart disease and symptoms [7] and
mitral valve repair is not always used or feasible [8,9]. In
addition, surgical risk remains high in a significant
percentage of contemporary patients who are elderly and
have comorbidities [3].
Recent advances
Two main techniques can be used for percutaneous
mitral valve repair: the edge-to-edge technique and
prosthetic ring annuloplasty. The edge-to-edge technique
mimics the surgical Alfieri procedure, which creates a
double mitral orifice by means of a few stitches securing
the two leaflets together in their midpart [10]. This
technique can be performed percutaneously using a clip
(MitraClip
®; Evalve, Inc., Menlo Park, CA, USA) made of
cobalt-chromium alloy and covered with polyethylene
terephthalate [11]. Another design involved the use of
one or more sutures deployed via a catheter-based
device. The technique requires general anaesthesia and
a transseptal approach with continuous fluoroscopic and
transoesophageal echographic guidance to catch the
leaflets at their coaptation point [12] (Figure 1). These
constraints mean that the technique is initially difficult
to learn and will limit its dissemination.
Current clinical experience is focused almost exclusively
on the clip technique (MitraClip) in 500 patients [13,14]
because the development of the other, suture-based
device has been abandoned [15]. In the initial EVEREST
(Endovascular Valve Edge-to-Edge Repair Study) registry
including 107 patients, severe MR was of degenerative
origin in around 80% of patients. Success rate and
procedure time improved steadily with experience. Sixty-
four percent of patients were discharged from hospital
with a clip and MR of less than grade 2/4, and the
procedure did not induce mitral stenosis [14-17]. The
procedure was well tolerated and 98% were free from
any complication in the expert centres involved in the
study. After 36 months, 66% of patients who underwent
a successful procedure were free from death, mitral valve
surgery, and MR greater than grade 2/4 [14]. Preliminary
studies also report satisfactory outcomes in patients at
high risk or in functional MR subsets.
Limitations of the edge-to-edge technique can be
anticipated: this technique, in isolation, does not address
the problem of annulus dilatation, which has been
shown to increase the risk of secondary residual
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F1000 Medicine Reportsregurgitation. In degenerative MR, its use will probably
be restricted to a limited percentage of patients. Residual
regurgitation carries the risk of insidious development of
left ventricular dysfunction.
Prosthetic ring annuloplasty is key in most cases of
surgical valve repair; data show that the diameter of the
mitral annulus can be reduced by inserting a constrain-
ing device in the proximate coronary sinus [18]. Several
devices are under investigation: the Carillon device
(Cardiac Dimensions Inc., Kirkland, WA, USA) uses a
nitinol wire with proximal and distal anchors [19]; the
Viacor device (Viacor, Inc., Wilmington, MA, USA) leads
to a decrease in anteroposterior diameter through the
application of pressure on the midportion of the
posterior leaflet by using several rigid elements placed
in a plastic sleeve [20]. These two devices can be
withdrawn if efficacy is not satisfactory or if the
circumflex artery is compromised. In the Monarc device
( E d w a r d sL i f e s c i e n c e sL L C ,I r v i n e ,C A ,U S A ) ,s e l f -
expanding stents are joined via a bridge that contracts
after 6 weeks [21]. All of these devices have had several
technical modifications over time.
Prosthetic ring annuloplasty is easier to perform than the
edge-to-edge technique and requires a catheterisation of
the coronary sinus through the jugular vein and the
delivery of the devices under fluoroscopic guidance
(Figure 2).
Figure 1. Percutaneous mitral valve repair: edge-to-edge technique using a clip (MitraClip; Evalve, Inc., Menlo Park, CA, USA)
Left panel: Right anterior oblique view. The clip is opened in the left ventricle, just below the mitral valves under transoesophageal echocardiographic guidance.
Right panel: Right anterior oblique view. The clip is closed at the coaptation point of the mitral valves and then released. Images courtesy of Peter Block.
Figure 2. Percutaneous mitral valve repair:
edge-to-edge technique using a suture
(Mobius; Edwards Lifesciences LLC, Irvine, CA, USA)
A left anterior oblique view of a clinical case of coronary sinus prosthetic
percutaneous annuloplasty is shown. The device is positioned in
the coronary sinus. A proximal stent is deployed in the proximal part
of the coronary sinus, and the distal stent is deployed in the distal part
of the coronary sinus. A constraining bridge connects the two stents.
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with functional MR suggest that the feasibility ranges
from 40% to 80% and that safety is satisfactory (83%
of implanted patients are event-free at 90 days). After
2 years, preliminary studies show that 80% of the
patients survive and most of them experience functional
improvement. Data on efficacy are more limited and
show a trend toward reduction of the degree of MR. In
addition, up to 30% of patients had some degree of
circumflex cinching, but this led to adverse events in only
a few cases [19-21].
The coronary sinus approach also has potential limita-
tions. The long-term benefits of mitral valve repair in
functional MR are debated [22]. The ring inserted into
the coronary sinus is localised to the posterior half of the
annulus, where surgeons usually use undersized and
complete rings [23]. The coronary sinus is 1 or 2 cm away
from the atrioventricular groove on the atrial side, and
this may also decrease the efficacy [24]. Finally, there is a
potential risk of cinching the circumflex artery whilst
crossing the coronary sinus [25,26]. This requires
noninvasive anatomic evaluation before the procedure
by using computed tomography imaging [25,26].
Several other devices and techniques are currently being
investigated experimentally or tested in humans for the
first time: ‘direct’ annuloplasty (such as transventricular
suture-based annuloplasty or subannular annuloplasty),
and ‘mitral cerclage’ annuloplasty, in which ventricular
remodelling using either transpericardial ventricular
remodelling with anchoring pads on either side of the
ventricle or a combination of anchors placed in the
coronary sinus and the atrial septum allows a tensioning
cable to be placed across the left atrium, applying tension
to reduce the septal lateral dimension. Finally, the first
experiments on percutaneous valve replacement have
also been performed.
Implications for clinical practice
The data we have on these new techniques are still
limited and suffer from a number of methodological
limitations. A lot of questions are still pending: more
clinical data are needed to accurately assess efficacy,
safety, and durability. The EVEREST II randomised study
comparing the percutaneous edge-to-edge technique
with surgery will be presented soon and further safety
and efficacy studies are to be conducted with percuta-
neous annuloplasty. It is essential to know whether
secondary intervention, either percutaneous (including
resynchronisation) or surgical, will be feasible. Imaging
guidance using three-dimensional transoesophageal
echocardiography will improve the performance of the
edge-to-edge technique. Overall, it is unlikely that these
new percutaneous techniques will reproduce the current
results of surgical valve repair; however, they may play a
role in patients with contraindications to or high risk for
surgery. This concerns a large population and may have a
great clinical impact [27].
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